Core Viewpoint - The company, Jinfang Pharmaceutical-B (02595.HK), announced that its sole sponsor and overall coordinator has fully exercised the over-allotment option as stated in the prospectus, involving a total of 13,386,000 H-shares, which accounts for approximately 15% of the total shares available for subscription before the exercise of any over-allotment option [1] Group 1 - The over-allotment shares will be issued at a price of HKD 20.39 per H-share, which is the same as the global offering price, excluding various fees [1] - The over-allotment shares will be used to cover the excess allocation in the international offering [1] - The stabilization period for the global offering has ended on October 16, 2025, which is the 30th day after the submission deadline for the Hong Kong public offering application [1]
劲方医药-B(02595.HK)悉数行使超额配股权、稳定价格行动及稳定价格期结束